Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Neurological Research and Practice|February 5, 2025
Shared prognostic information in amyotrophic lateral sclerosis - systematic assessment of the patients' perception of neurofilament light chain and the ALS functional rating scaleLukas Maximilian Möhwald, André Maier, Torsten Grehl, et al.
Muscle & Nerve|March 17, 2023
Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practiceThomas Meyer, Peggy Schumann, Patrick Weydt, et al.
Neurological Research and Practice|April 27, 2025
Motor phenotypes of amyotrophic lateral sclerosis - a three-determinant anatomical classification based on the region of onset, propagation of motor symptoms, and the degree of upper and lower motor neuron dysfunctionThomas Meyer, Matthias Boentert, Julian Großkreutz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 1, 2018
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approachAndreas Funke, Susanne Spittel, Torsten Grehl, et al.
Archivos De Bronconeumologia|May 22, 2023
Effect of Intensity of Home Noninvasive Ventilation in Individuals With Neuromuscular and Chest Wall Disorders: A Systematic Review and Meta-Analysis of Individual Participant DataMathieu Delorme, Antoine Leotard, Marius Lebret, et al.
Annals of Neurology|December 19, 2019
Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral SclerosisAlbert C Ludolph, Johannes Dorst, Jens Dreyhaupt, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 17, 2026
ALS motor phenotypes: a revised 'OPM' classificationThomas Meyer, Nicola Ticozzi, Markus Weber, et al.
The Lancet. Neurology|June 24, 2018
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trialAlbert C Ludolph, Joachim Schuster, Johannes Dorst, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 20, 2026
Minimum important slowing of disease progression as determined by the ALS functional rating scale - a survey of patient expectations toward disease-modifying drugs in ALSThomas Meyer, André Maier, Torsten Grehl, et al.
European Journal of Neurology|January 19, 2024
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosisJoachim Schuster, Jens Dreyhaupt, Karla Mönkemöller, et al.
Pageof 11